Elevated Amylase and Lipase Levels in Patients Using Glucagonlike Peptide-1 Receptor Agonists or Dipeptidyl-Peptidase-4 Inhibitors In the Outpatient Setting

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Alan J. Garber, Robert R. Henry, Robert E. Ratner et al. · The Lancet · 2008 · 1.1K citations

Medicine, Endocrinology, Pharmacotherapy +13

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

Michael Elashoff, Aleksey V. Matveyenko, Belinda Gier et al. · Gastroenterology · 2011 · 931 citations · Full text

Medicine, Endocrinology, Oncology +14

Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

Michel Marre, J. Shaw, Michael Brändle et al. · Diabetic Medicine · 2009 · 815 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes

Rebecca Noel, Daniel Braun, Ruth E. Patterson et al. · Diabetes Care · 2009 · 437 citations · Full text

Medicine, Internal Medicine, Clinical Epidemiology +16

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

David D. Dore, John D. Seeger, K. Arnold Chan · Current Medical Research and Opinion · 2009 · 329 citations

Pharmacy, Internal Medicine, Pharmacology +17